Aim And Background: As rectal cancer diagnosis becomes more prevalent due to the increased awareness caused by campaigns, this study aims to focus on the demographics of patients diagnosed with rectal cancer in the Kingdom of Bahrain.
Methods: A retrospective cross-sectional study design was conducted on 184 patients diagnosed with primary or second primary rectal cancer. Stage and site of tumor at diagnosis, gender, BMI, family history, histology, and metastasis are discussed throughout the paper.
Results: The majority of the population (85.9%) were Bahraini, with males (57.6%) being more prevalent. A little over 50% of patients diagnosed with rectal cancer were aged 60 years or younger. In most cases, the tumors were spotted in the lower rectum (48.9%) and were diagnosed by the appearance of symptoms (91.8%). Kaplan-Meier Survival analysis showed that the overall survival for males is 95.3% and for females 93.6% for 1 year.
Conclusion: The high number of Bahraini males diagnosed with rectal cancer highlights the importance of early screening and detection. The prevalence of the tumor in the lower rectum suggests the need for improved education on recognizing symptoms and seeking medical attention. Further research is required to establish a comprehensive national screening program for rectal cancer in Bahrain.
Clinical Significance: Understanding the demographic and clinical characteristics of rectal cancer patients in the Kingdom of Bahrain is required to target early screening and public awareness. The findings of this study provide a solid foundation for future developments in rectal cancer diagnosis and treatment to improve survival outcomes.
How To Cite This Article: Juma IM, Saeed MF, Hamel LR, Epidemiology of Rectal Cancer Patients in the Kingdom of Bahrain: A Retrospective Cohort Study. Euroasian J Hepato-Gastroenterol 2024;14(2):205-209.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714114 | PMC |
http://dx.doi.org/10.5005/jp-journals-10018-1454 | DOI Listing |
Aims: With the recently validated tool for estimating chronic pain after colorectal cancer surgery, the aims of this study were to calculate the prevalence and to identify predictive risk factors for chronic pain after colorectal cancer treatment.
Method: Clinical data from colorectal cancer patients treated between 2001 and 2014 were obtained from the Danish Colorectal Cancer Group database. In 2016, all survivors were invited to participate in a national cross-sectional questionnaire study on long-term functional outcomes, including the chronic pain questionnaire.
Clin Transl Radiat Oncol
March 2025
University Medical Center Utrecht, Department of Radiation Oncology, Utrecht, the Netherlands.
Background And Purpose: This study assessed the treatment time of online adaptive (i.e. Adapt-to-Shape, ATS) and virtual couch shift (i.
View Article and Find Full Text PDFAME Case Rep
October 2024
Department of Oncology, Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
Background: Hyperammonemic encephalopathy caused by high-dose infusion of 5-fluorouracil (5-FU) is a rare adverse reaction in rectal cancer patients with an incidence rate of 5.7%. Although the patient could be restored to normal after supportive treatments, the occurrence of this side effect was still inevitable.
View Article and Find Full Text PDFAME Case Rep
November 2024
Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Background: Mucinous adenocarcinoma is a rare type of colorectal cancer (CRC) associated with poor prognosis, particularly when it includes signet ring cell components. Furthermore, its rate of microsatellite instability-high (MSI-H) is significantly higher compared to non-mucinous adenocarcinoma. Immunotherapy has emerged as the standard treatment for MSI-H metastatic CRC (mCRC).
View Article and Find Full Text PDFFEBS Open Bio
January 2025
Clinical Measurement Sciences, Global Research & Development, EMD Serono, Billerica, MA, USA.
MAPK signaling activation is an important driver event in colorectal cancer (CRC) tumorigenesis that informs therapy selection, but detection by liquid biopsy can be challenging. We analyze real-world comprehensive genomic profiling (CGP) data to explore the landscape of alterations in BRAF or RAS in CRC patients (N = 51 982) and co-occurrence with other biomarkers. A pathogenic RAS or BRAF alteration was found in 63.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!